Life Sciences Tools and Services
Company Overview of Life Technologies Corporation
Life Technologies Corporation operates as a life sciences company. The company’s Research Consumables business group offers molecular and cell biology reagents, endpoint PCR, and other benchtop instruments and consumables, such as RNAi, DNA synthesis, sample prep, transfection, cloning and protein expression profiling and protein analysis, cell culture media used in research, stem cells and related tools, cellular imaging products, antibodies, and cell therapy related products. Its Genetic Analysis business group provides capillary electrophoresis (CE) instruments used for research applications and various CE consumables; real-time and digital qPCR instruments used in research applications; ...
5791 Van Allen Way
Carlsbad, CA 92008
Founded in 1987
Key Executives for Life Technologies Corporation
President of Genetic and Medical Sciences Organization
President of Molecular Biology Systems
President of Ion Torrent and Chief Operating Officer of Ion Torrent
Chief Information Officer and Senior Vice President
Head of Global Operations
Compensation as of Fiscal Year 2017.
Life Technologies Corporation Key Developments
The Supreme Court Rules in Favor of Life Technologies Corporation in a Patent Infringement Case
Feb 23 17
The Supreme Court has sided with Life Technologies Corp. in a patent infringement case that limits the international reach of U.S. patent laws. The justices ruled unanimously on February 22, 2017 that the company's shipment of a single part of a patented invention for assembly in another country did not violate patent laws. Life Technologies supplied an enzyme used in DNA analysis kits to a plant in London and combined it with several other components to make kits sold worldwide. Promega Corp. sued, arguing that the kits infringed a U.S. patent. A jury awarded $52 million in damages to Promega. A federal judge set aside the verdict and said the law did not cover export of a single component.
Enzo Life Sciences, Inc. Enters into Settlement and License Agreement with Life Technologies Corporation
May 16 16
Enzo Life Sciences Inc. entered into a Settlement and License Agreement as of May 16, 2016 with Life Technologies Corporation with respect to an action between Enzo Life and Life Technologies Corporation before the U.S. District Court for the District of Delaware alleging infringement of its U.S. Patents Nos. 6,992,180 entitled Oligo - or Polynucleotides Comprising Phosphate-Moiety Labeled Nucleotides and 7,064,197 entitled System, Array and Non-Porous Solid Support Comprising Fixed or Immobilized Nucleic Acids. As a result of the Agreement, Life Technologies will pay to Enzo Life $35,000,000 no later than seven business days following the effective date in settlement of the aforementioned case. This settlement resolving the dispute between Enzo Life Sciences and Life Technologies impacts only one of 11 cases originally brought by Enzo in the United States District Court for the District of Delaware alleging patent infringements against various companies, four of which are now resolved and seven of which remain pending. This settlement does not affect Enzo Life Science's action brought in Federal District Court in New Haven, CT against Life Technologies' predecessors Applera Corp. and Tropix, Inc, which remains on appeal in the U.S. Court of Appeals for the Federal Circuit.
Similar Private Companies By Industry
Recent Private Companies Transactions
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries